Prions are composed solely of an alternatively folded isoform of the prion protein (PrP), designated PrP Sc . The polyoxometalate phosphotungstic acid has been used to separate PrP Sc from its precursor PrP C by selective precipitation; notably, native PrP Sc has not been solubilized by using nondenaturing detergents. Because of the similarities between PrP Sc and lipoproteins with respect to hydrophobicity and formation of phosphotungstic acid complexes, we asked whether these molecules are bound to each other in blood. Here we report that prions from the brains of patients with sporadic Creutzfeldt-Jakob disease (CJD) bind to very low-density (VLDL) and low-density ( Sc , no procedure has been developed except for incorporation of the protein into liposomes (1, 2). The hydrophobic properties of PrP Sc not only have impeded biological investigations but also have prevented structural studies at atomic resolution.
P
rions are composed solely of an alternatively folded isoform of the prion protein, designated PrP Sc . Despite numerous efforts to solubilize native PrP Sc , no procedure has been developed except for incorporation of the protein into liposomes (1, 2) . The hydrophobic properties of PrP Sc not only have impeded biological investigations but also have prevented structural studies at atomic resolution.
During the development of an immunoassay for PrP Sc that does not depend upon limited proteolysis to hydrolyze the precursor protein designated PrP C , we found that the Na salt of phosphotungstic acid (PTA) selectively complexes with PrP Sc (3) . PTA is a water-soluble salt featuring the nearly spherical trianion [PW 12 O 14 ] 3Ϫ that belongs to a broad class of polynuclear transition metal-oxo complexes known as polyoxometalates (POMs; see ref. 4) . Recently, two of us (J.G.S. and S.B.P.) investigated the mechanism of selective complex formation between Keggin-type POMs and PrP Sc using a series of POM analogues (5) . The ability of POMs to complex with PrP Sc as well as lipoproteins (6) raised the possibility that these two hydrophobic proteins might copurify.
We began by examining the distribution of human (Hu) PrP Sc in human plasma fractions spiked with sporadic CreutzfeldtJakob disease (sCJD) prions from human brain. CJD prions were found with very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL) but not with high-density lipoproteins (HDL) or any other plasma component. In addition to binding to purified VLDL and LDL particles, PrP Sc was also found to bind apolipoprotein B (apoB), which is the major protein component of both VLDL and LDL. The positive cooperativity of the binding and high avidity of apoB, VLDL, and LDL for native HuPrP Sc determined in capture-affinity assay raised the possibility that these lipoprotein particles may feature in the pathogenesis of prion diseases. Whether our findings will form the basis of an antemortem diagnostic test for prions remains to be established.
Results
To determine the distribution of PrP Sc in four different plasma fractions, 15% (wt͞vol) brain homogenates in 4% Sarkosyl from sCJD patients and controls were diluted 100-fold into pooled normal plasma (Fig. 5 , which is published as supporting information on the PNAS web site). The protease-resistant core of PrP Sc , denoted PrP 27-30, partitioned into the VLDL and LDL particles, whereas traces were found in the immunoglobulins but none in HDL or albumin fraction.
High-Affinity Binding of sCJD Prions to LDL. To investigate the interaction of PrP Sc with plasma VLDL or LDL, we measured the capture of native PrP Sc by purified LDL or HDL using the CDI format. We coated plates with serial dilutions of purified lipoproteins and then exposed them to PrP Sc precipitated with PTA from sCJD brain homogenate. After washing the plates to remove unbound PrP Sc , we denatured the PrP Sc for it to bind to the europium (Eu)-labeled mAb 3F4 used for detection. After denaturation of PrP Sc , which was accomplished with 4 M guanidine hydrochloride (Gdn⅐HCl) at 80°C for 20 min, the Gdn⅐HCl was removed, and the plates were washed again. We observed that PrP 27-30 in sCJD brain homogenates was captured as a function of the concentration of LDL (Fig. 1A) and VLDL (data not shown). Despite a similar lipid composition (6), HDL did not capture PrP 27-30 ( Fig. 1 A) .
We next asked what fraction of PrP Sc was released from LDL upon denaturation. As shown in Fig. 1B , measurable PrP Sc was released upon denaturation. LDL-coated plates were exposed to PrP Sc from sCJD brain homogenates that had been precipitated with PTA and then denatured by using Gdn⅐HCl at 80°C for 20 min. The PrP Sc bound to LDL was measured by adding the detection antibody to the plate after the Gdn⅐HCl was removed (Fig. 1B, circles) . The unbound PrP Sc in the Gdn⅐HCl was measured by the CDI after the sample was diluted 10-fold. As shown, the level of unbound PrP Sc is Ϸ10% of that found for the PrP Sc that remained bound (Fig. 1B, triangles) . When we take into account that the unbound PrP Sc sample was diluted 10-fold before the CDI to lower the Gdn⅐HCl concentration below a level that would denature the capture and detection antibodies, the CDI readings are equal to the readings of the original LDL-coated plate (Fig. 1) . Therefore, we conclude that Ϸ50% of the PrP Sc bound to LDL particles is released by the Gdn⅐HCl denaturation procedure.
We also examined whether LDL can capture prions directly from sCJD brain homogenate. LDL-coated plates were exposed to PrP 27-30 that was generated from sCJD brain homogenate by limited digestion with proteinase K; the level of PrP 27-30 bound, determined by the direct CDI, was Ϸ50-fold lower than that in the PTA precipitate ( Fig. 1B ; compare circles and squares). The lower signal for the brain homogenate is largely due to the 20-fold dilution necessary to diminish the concentration of Sarkosyl in the homogenate before PrP Sc binding to LDL. Apparently, Sarkosyl inhibits the interaction between PrP Sc and LDL (data not shown).
Because LDL, HDL, and prions polymerized into amyloid rods are visible by electron microscopy, we performed a series of mixing experiments. We examined the sCJD preparations using immunolabeling and negative-stain electron microscopy. PrP 27-30 in sCJD brain homogenates polymerizes into rod-shaped particles, as reported ( Fig. 2A; see ref. 7 ). The sCJD rods appear to be more rigid with more well defined contours than those obtained from prion-infected Syrian hamster brains (3, 8) . Upon removal of the PTA by dialysis, the morphology of the human CJD rods remained unchanged. Immunogold labeling with an ␣-PrP mAb confirmed that the rods contain rPrP Sc (Fig. 2B ). Negative staining of purified preparations of LDL and HDL revealed the typical sizes and morphologies for both lipoprotein particles ( Fig. 2 C and D) .
After mixing PTA-precipitated prion rods from sCJD brain with 0.3 mg͞ml LDL or HDL, we observed that almost all LDL particles bound to the rods (Fig. 2E ). Only Ϸ10% of LDL particles were observed at distances Ͼ50 nm from the prion rods. LDL particles bound to prion rods showed a pronounced propensity to fuse into larger aggregates (Fig. 2E ). This aggregation was presumably triggered by the extreme hydrophobicity of PrP 27-30 (2, 9) . In contrast, HDL particles were found all over the grid surface, without any apparent preference for PrP 27-30 ( Fig. 2F ). More than 95% of HDL particles were at distances Ͼ50 nm from the human prion rods, demonstrating that HDL has no perceptible propensity to bind PrP 27-30. HDL particles that were in direct proximity of PrP 27-30 showed no aggregation and retained their typical size and structure. These ultrastructural findings combined with the immunoassay data presented above argue that PrP Sc binds to LDL but not to HDL particles.
To estimate the parameters of the binding interaction, the series of isotherms from the direct assay of LDL-captured PrP 27-30 and from the sandwich CDI of released PrP 27-30 were fitted to the Hill equation (see Eq. 1 in Supporting Text, which is published as supporting information on the PNAS web site) as a function of apoB concentration in LDL (Fig. 1) . The results indicate that native human PrP 27-30 binds to LDL with positive cooperativity, with an apparent binding affinity (K d app ) in the range of 30-60 pM ( Fig. 1 and Table 1) . Similar values were obtained with purified VLDL (data not shown). The Hill coefficient data indicate a potential stoichiometry of three to four HuPrP Sc molecules binding to one LDL.
High-Affinity Capture of sCJD Prions by apoB. Because the principal protein component of both VLDL and LDL is apoB, we examined the ability of apoB to capture PrP 27-30 in sCJD brain homogenates or PTA precipitates. Although the binding of rPrP Sc to apoB displayed positive cooperativity similar to that seen with the LDL and VLDL particles, the K d app values were reduced 4-to 10-fold ( Fig. 3 and Table 1 ). These data suggest that apoB may be the binding partner for PrP Sc in both VLDL and LDL, but that lipid components influence binding affinity and possibly stoichiometry. . Lipoprotein-coated plates were exposed to rPrP Sc isolated in 5% sCJD brain homogenates after a 1-h treatment with 10 g͞ml PK in the presence of 4% Sarkosyl followed by precipitation with 0.32% PTA and 2.6 mM MgCl 2. (B) LDL-coated plates were exposed to 20-fold diluted 5% sCJD brain homogenates in 4% Sarkosyl (sCJD͞BH) treated previously with 10 g͞ml PK for 1 h at 37°C or to rPrP Sc precipitated from PK-treated sCJD brain homogenate with 0.32% PTA and 2.6 mM MgCl 2 (sCJD͞PTA). The rPrP Sc bound to LDL was denatured by 4 M Gdn⅐HCl for 20 min at 80°C and detected by Eu-labeled 3F4 mAb added to the plate after the Gdn⅐HCl was removed (circles). The released PrP Sc in the Gdn⅐HCl was measured by the CDI after the sample was diluted 10-fold (triangles). PrP Sc in sCJD brain homogenates designated sCJD͞BH (squares) was bound to LDL-coated plates and measured by adding the detection Eu-labeled 3F4 mAb to the plate after the Gdn⅐HCl was removed. Samples were diluted (20-fold for sCJD͞BH and 2. Because Ϸ50% of HuPrP 27-30 exposed to 4 M Gdn⅐HCl at 80°C for 20 min remained bound to LDL particles (Fig. 1B) , we examined the binding of recombinant HuPrP composed of residues 90-231, designated recHuPrP(90-231). The binding of recHuPrP(90-231) to LDL was measured by using the CDI ( Table 1 ). The Hill coefficient data indicate a stoichiometr y of Ϸ1 denatured recHuPrP(90-231) molecule binding to one LDL particle or The raw fluorescence data were fit to the Hill function (Eq. 
Discussion
The lipophilic nature of PrP Sc is similar to that of the apolipoproteins. Numerous attempts to remove the lipids bound to native PrP Sc and substitute nondenaturing detergents have been unsuccessful (11, 12) . Functional solubilization was achieved by dispersion of PrP Sc into liposomes (13) . Although the copartioning of PrP Sc and LDL was not surprising, the cooperative binding of PrP Sc to LDL and apoB, with such high affinities (Table 1) , but not to HDL, was unexpected ( Figs. 1 and 2 ). When PrP Sc is formed from PrP C , this process seems to occur in cholesterol-rich microdomains often referred to as rafts or caveolae-like domains (CLDs; see ref. 14). Rafts or CLDs enriched for PrP C and PrP Sc have been isolated by flotation gradients (15, 16) . Depletion of cholesterol from cultured cells was found to inhibit the formation of nascent PrP Sc (14) .
Prions in Blood.
Recently, variant CJD that is found in teenagers and young adults (17) appears to have been transmitted from prion-infected donors to three transfusion recipients (18) (19) (20) . Such findings are consistent with earlier reports of low levels of prions in blood (21) (22) (23) and the replication of prions in the lymphoreticular system (24) (25) (26) (27) (28) (29) . The distribution of prions in blood has been difficult to resolve, because the levels of infectivity are so low (21, (30) (31) (32) . Whether some prions are nonspecifically bound to circulating lymphocytes, perhaps by PrP C , or whether they reproduce at low levels in a distinct set of lymphoid cells is unclear (33) (34) (35) (36) . Notably, transplantation of bone marrow from WT mice restored prion replication in the spleens of Prnp 0/0 mice (27) . In contrast to studies on white blood cells summarized above, our results suggest a measurable fraction of prion infectivity is likely to be associated with VLDL and LDL particles. Should prion infectivity be found in the VLDL or LDL fractions, then the utility of leukodepletion (32, 37) will need to be reconsidered.
Our finding that PrP Sc binds to LDL particles is not the first report of PrP Sc binding to a plasma protein. Other investigators reported mouse Rocky Mountain Laboratory (RML) prions bind to plasminogen (38) , but subsequent studies by others demonstrated that the affinity of PrP for plasminogen is low (M. Vey, personal communication; see ref. 39) . Additionally, studies in transgenic and knockout mice indicate that plasminogen expression does not influence the prion replication rate or the pathogenesis of RML prion infection (40) .
Lipoproteins and Neurodegenerative Diseases. Although the function, if any, of lipoproteins in the pathogenesis of prion disease is unknown, the role of apolipoprotein E (apoE) in modulating the onset of Alzheimer's disease is well documented (41) . Attempts to correlate the apoE isotype with sCJD were unsuccessful (42, 43) , and apoE-deficient mice exhibited incubation times for RML prions that were indistinguishable from those in WT mice (44) .
Receptors for both apoE and apoB have been identified in the CNS, but apoB is not expressed in brain (45) . Each human LDL particle contains Ϸ3,000 lipid molecules and one apoB protein consisting of 4,536 amino acids (46) . LDLs are composed of several distinct size and density subclasses (47); whether PrP Sc preferentially binds to a particular LDL subclass remains to be determined.
Because Ͼ50 mutations in the apoB gene have been recorded, it will be of interest to determine whether any modify the age of onset, duration of the clinical course, or the constellation of neurologic deficits in CJD. Many apoB mutants have been identified that diminish the binding of apoB to LDL receptors (48, 49) .
The affinity of native PrP Sc for apoB appears to be much greater than that of any PrP Sc -specific antibody or aptamer reported to date (50) (51) (52) (53) . The binding of native PrP Sc to apoB was enhanced up to 10-fold by the additional lipids found in LDLs (Table 1) . This increase may be due to conformational changes in either apoB or PrP Sc that are induced by the additional lipids (54) .
It will be of interest to determine whether mixing naturally occurring or synthetic prions (55) with LDL before inoculation will alter the incubation time after intracerebral (i.c.) or i.p. inoculation. Whether LDL particles or a subclass will facilitate retention of prions in the brain after i.c. inoculation is unknown. In other investigations, we found that only Ϸ1% of injected prions can be found in the brain 48 h after i.c. inoculation (56) . It will also be important to assess whether partitioning of prions into LDL particles alters the strain-specified properties of a particular inoculum.
Diagnostic Tests for Prions. Our findings are encouraging with respect to the development of a reliable antemortem test for prions. Perhaps the sensitivity and reliability of an antemortem blood test for prions can be increased by fractionation of LDLs into one or more of the subclasses noted above. How early in the disease course prions will be detected in sCJD cases is unknown; likewise, the time at which prions can be detected in LDL particles in familial cases of prion disease remains to be established. Whether such a blood test will be equally applicable to all mammals is also uncertain.
Whether all VLDL and LDL particles should be removed from human blood and plasma that is used in transfusions remains to be determined. Such an approach may find application in some higher-risk populations, such as in Britain, where it has been estimated that thousands of people are replicating variant CJD prions in their lymphoid tissues (28) .
It should be possible to engineer a mutant apoB protein-lipid complex with a very high affinity for PrP Sc . Such a mutant apoB might find application first as a capture moiety in a prion diagnostic test like the CDI and then as a pharmacotherapeutic. Whether an i.v.-administered apoB mutant might function analogously to anti-A␤ antibodies being used in the treatment of Alzheimer's disease remains to be established (57) (58) (59) . Interestingly, expression of human apoE in transgenic mice reduced A␤ deposition in a model of Alzheimer's disease (60) .
Materials and Methods
The LDL, HDL, and VLDL fractions from healthy donors were purified as described in Supporting Text (61) .
The preparation and purification of recHuPrP(90-231) were as described for SHaPrP(90-231) (see ref. 10 ). The molecular mass for recHuPrP(90-231) was 16,059 Da, as determined by MS. The refolding of recHuPrP(90-231) into an ␣-helical protein is described in Supporting Text.
The CDI data described in this paper were generated with Eu-labeled mAb 3F4 (62, 63) or recHuMFab P (64) .
Partitioning of CJD prions during fractionation of human plasma spiked with sCJD brain homogenate was analyzed by using a modified protocol for purification of lipoproteins (6) . The details of the plasma fractionation using PTA and MgCl 2 are described in Supporting Text.
Electron microscopy (65) used formvar͞carbon-coated 200-mesh copper grids that were glow-discharged before staining. The grids were negatively stained with ammonium molybdate. Immunolabeling was performed by using the recHuMFab R2. Details are described in Supporting Text.
We thank the subjects and their families for their contributions to this study, the staff of the Stanford Blood Center for making available healthy donor blood units, and Kristen Schardein Fox for collecting plasma specimens from CJD patients. 
